Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Millennium Pharmaceuticals, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Voluntary consent form
Diagnosis of GI malignancy with a GCC protein expressing tumor
Male or female patients 18 years or older with measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
Female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or agree to abstain from heterosexual intercourse
Male patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate bone marrow, hepatic and renal function as specified in the protocol
You may not be if
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Any serious medical or psychiatric illness that could interfere with the completion of treatment
Major surgery or treatment with investigational drug before the first dose
Serious infection within 14 days before the first dose of study drug
Known HIV, inflammatory bowel disease, viral hepatitis or cerebral/meningeal brain metastases
Patients with cardiovascular conditions specified in protocols
Patients with history of another primary malignancy not in remission for at least 3 years
Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons.
Clareo Health | Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C
